Frost Radar™: Pharmaceutical Commercialization Solutions and Services, 2024

HealthcareFrost Radar™: Pharmaceutical Commercialization Solutions and Services, 2024

A Benchmarking System to Spark Companies to Action - Innovation That Fuels New Deal Flow and Growth Pipelines

RELEASE DATE
28-Oct-2024
REGION
Global
Deliverable Type
Frost Radar
Research Code: PFP2-01-00-00-00
SKU: HC_2024_1089
AvailableYesPDF Download
$4,950.00
In stock
SKU
HC_2024_1089

Frost Radar™: Pharmaceutical Commercialization Solutions and Services, 2024
Published on: 28-Oct-2024 | SKU: HC_2024_1089

Need more details?
$4,950.00
DownloadLink
Need more details?

With an inclination toward patient-centric care delivery, the pharma industry follows a robust, step-by-step approach to market commercialization, with a clear understanding of the market stakeholders, segments, and post-launch forecasts to create seamless go-to-market strategies, develop a positive image, and instill confidence among healthcare providers using scientific data and testimonials. Pharma companies collaborate with third-party logistics providers and adopt adaptive supply chain strategies such as dual sourcing, stockpiling, and advanced scenario planning while tapping the capabilities of established distribution partners to avoid risks and disruptions.

Clearly defined marketing and sales strategies allow pharma companies to navigate regulatory bodies, end-user segments, and other technology vendors.

This Frost Radar™ includes companies that provide cutting-edge solutions and services across the commercialization value chain. The focus areas include supporting managed markets with respect to market access strategies, using AI/ ML-enabled platforms, and omnichannel marketing and sales strategies. Most profiled companies have a global presence.

Frost & Sullivan analyzes numerous companies in an industry. Those selected for further analysis based on their leadership or other distinctions are benchmarked across 10 Growth and Innovation criteria to reveal their position on the Frost Radar™. The publication presents competitive profiles of each company on the Frost Radar™ considering their strengths and the opportunities that best fit those strengths.

Strategic Imperative

Strategic Imperative (continued)

Growth Environment

Growth Environment (continued)

Frost Radar™: Pharmaceutical Commercialization Solutions and Services, 2024

Frost Radar™ Competitive Environment

Frost Radar™ Competitive Environment (continued)

Frost Radar™ Competitive Environment (continued)

Frost Radar™ Competitive Environment (continued)

Aktana

Aktana (continued)

Aktana (continued)

Aktana (continued)

Axtria

Axtria (continued)

Axtria (continued)

EVERSANA

EVERSANA (continued)

EVERSANA (continued)

EVERSANA (continued)

iNIZIO

iNIZIO (continued)

iNIZIO (continued)

IQVIA

IQVIA (continued)

IQVIA (continued)

OPEN Health

OPEN Health (continued)

OPEN Health (continued)

OPEN Health (continued)

Syneos Health

Syneos Health (continued)

Syneos Health (continued)

Syneos Health (continued)

Syneos Health (continued)

Trinity Life Sciences

Trinity Life Sciences (continued)

Trinity Life Sciences (continued)

Trinity Life Sciences (continued)

Viseven

Viseven (continued)

Viseven (continued)

ZS Associates

ZS Associates (continued)

ZS Associates (continued)

Best Practices

Growth Opportunities

Frost Radar™: Benchmarking Future Growth Potential 2 Major Indices, 10 Analytical Ingredients, 1 Platform

Frost Radar™: Benchmarking Future Growth Potential 2 Major Indices, 10 Analytical Ingredients, 1 Platform (continued)

Significance of Being on the Frost Radar™

Frost Radar™ Empowers the CEO’s Growth Team

Frost Radar™ Empowers Investors

Frost Radar™ Empowers Customers

Frost Radar™ Empowers the Board of Directors

Next Steps

Legal Disclaimer

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.

With an inclination toward patient-centric care delivery, the pharma industry follows a robust, step-by-step approach to market commercialization, with a clear understanding of the market stakeholders, segments, and post-launch forecasts to create seamless go-to-market strategies, develop a positive image, and instill confidence among healthcare providers using scientific data and testimonials. Pharma companies collaborate with third-party logistics providers and adopt adaptive supply chain strategies such as dual sourcing, stockpiling, and advanced scenario planning while tapping the capabilities of established distribution partners to avoid risks and disruptions. Clearly defined marketing and sales strategies allow pharma companies to navigate regulatory bodies, end-user segments, and other technology vendors. This Frost Radar includes companies that provide cutting-edge solutions and services across the commercialization value chain. The focus areas include supporting managed markets with respect to market access strategies, using AI/ ML-enabled platforms, and omnichannel marketing and sales strategies. Most profiled companies have a global presence. Frost & Sullivan analyzes numerous companies in an industry. Those selected for further analysis based on their leadership or other distinctions are benchmarked across 10 Growth and Innovation criteria to reveal their position on the Frost Radar . The publication presents competitive profiles of each company on the Frost Radar considering their strengths and the opportunities that best fit those strengths.
More Information
Deliverable Type Frost Radar
Author Aarti Siddhesh Chitale
Industries Healthcare
No Index No
Is Prebook No
Keyword 1 pharmaceutical commercialization
Keyword 2 pharma innovation
Keyword 3 drug marketing solutions
Podcast No
WIP Number PFP2-01-00-00-00